ATC Group: J06BB04 Hepatitis B immunoglobulin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J06BB04 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J06 Immune sera and immunoglobulins
3 J06B Immunoglobulins
4 J06BB Specific immunoglobulins
5 J06BB04 Hepatitis B immunoglobulin

Active ingredients in J06BB04

Active Ingredient

Human hepatitis B immunoglobulin solution for infusion contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against hepatitis B virus surface antigen (HBs). It is used for the immunoprophylaxis of hepatitis B and the prevention of hepatitis B virus re-infection after liver transplantation for hepatitis B induced liver failure.

Related product monographs

Document Type Information Source  
 HEPAGAM B Solution for infusion MPI, US: SPL/PLR FDA, National Drug Code (US)
 HEPATECT CP Solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 HYPERHEP B Solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 ZUTECTRA Solution for injection MPI, EU: SmPC European Medicines Agency (EU)

Medicines in this ATC group

United States (US)

Brazil (BR)

Canada (CA)

Croatia (HR)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Italy (IT)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

South Africa (ZA)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.